Crispr Therapeutics Stock Options
| CRSP Stock | USD 58.09 0.50 0.87% |
Crispr Therapeutics' latest option contracts expiring on January 23rd 2026 are carrying combined implied volatility of 0.67 with a put-to-call open interest ratio of 0.29 over 34 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on January 23rd 2026. The total put volume is at 15.0, with calls trading at the volume of 10.0. This yields a 1.5 put-to-call volume ratio.
Open Interest Against January 23rd 2026 Option Contracts
2026-01-23
The chart above shows Crispr Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Crispr Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Crispr Therapeutics' option, there is no secondary market available for investors to trade.
Crispr Therapeutics Maximum Pain Price Across 2026-01-23 Option Contracts
Max pain occurs when Crispr Therapeutics' market makers reach a net positive position across all Crispr Therapeutics' options at a strike price where option holders stand to lose the most money. By contrast, Crispr Therapeutics' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Crispr Therapeutics
Analyzing Crispr Therapeutics' in-the-money options over time can help investors to take a profitable long position in Crispr Therapeutics regardless of its overall volatility. This is especially true when Crispr Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Crispr Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Crispr Therapeutics' stock while costing only a fraction of its price.
Crispr Therapeutics In The Money Call Balance
When Crispr Therapeutics' strike price is surpassing the current stock price, the option contract against Crispr Therapeutics AG stock is said to be in the money. When it comes to buying Crispr Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Crispr Therapeutics AG are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Crispr Current Options Market Mood
Crispr Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Crispr Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Using current Crispr Therapeutics' option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.
Rule 16 of the current Crispr contract
Base on the Rule 16, the options market is currently suggesting that Crispr Therapeutics AG will have an average daily up or down price movement of about 0.0419% per day over the life of the 2026-01-23 option contract. With Crispr Therapeutics trading at USD 58.09, that is roughly USD 0.0243. If you think that the market is fully incorporating Crispr Therapeutics' daily price movement you should consider buying Crispr Therapeutics AG options at the current volatility level of 0.67%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Purchasing Crispr Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Crispr calls. Remember, the seller must deliver Crispr Therapeutics AG stock to the call owner when a call is exercised.
Crispr Therapeutics Option Chain
When Crispr Therapeutics' strike price is surpassing the current stock price, the option contract against Crispr Therapeutics AG stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Crispr Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Crispr. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Crispr. It also shows strike prices and maturity days for a Crispr Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | CRSP260123C00075000 | 7 | 75.0 | 0.0 - 2.9 | 1.4 | Out |
Call | CRSP260123C00070000 | 0 | 70.0 | 0.05 - 3.5 | 0.05 | |
Call | CRSP260123C00067000 | 1 | 67.0 | 0.35 - 4.0 | 2.6 | Out |
Call | CRSP260123C00066000 | 0 | 66.0 | 0.6 - 4.3 | 0.6 | |
Call | CRSP260123C00065000 | 3 | 65.0 | 0.9 - 3.2 | 3.15 | Out |
Call | CRSP260123C00064000 | 0 | 64.0 | 1.2 - 4.5 | 1.2 | |
Call | CRSP260123C00063000 | 0 | 63.0 | 1.5 - 4.8 | 1.5 | |
Call | CRSP260123C00062000 | 4 | 62.0 | 2.85 - 4.3 | 3.07 | Out |
Call | CRSP260123C00061000 | 0 | 61.0 | 2.2 - 5.5 | 2.2 | |
Call | CRSP260123C00060000 | 24 | 60.0 | 3.7 - 5.8 | 3.9 | Out |
Call | CRSP260123C00058000 | 1 | 58.0 | 3.4 - 6.6 | 4.89 | Out |
Call | CRSP260123C00057000 | 7 | 57.0 | 4.6 - 7.1 | 5.5 | In |
Call | CRSP260123C00055000 | 7 | 55.0 | 4.5 - 8.5 | 5.1 | In |
Call | CRSP260123C00054000 | 12 | 54.0 | 5.1 - 9.0 | 7.3 | In |
Call | CRSP260123C00053000 | 12 | 53.0 | 5.9 - 9.1 | 6.7 | In |
Call | CRSP260123C00050000 | 2 | 50.0 | 8.0 - 11.0 | 9.01 | In |
Put | CRSP260123P00075000 | 0 | 75.0 | 16.8 - 20.0 | 16.8 | In |
Put | CRSP260123P00070000 | 1 | 70.0 | 12.4 - 15.5 | 14.0 | In |
Put | CRSP260123P00067000 | 0 | 67.0 | 9.8 - 13.0 | 9.8 | In |
Put | CRSP260123P00066000 | 0 | 66.0 | 9.0 - 12.3 | 9.0 | In |
Put | CRSP260123P00065000 | 2 | 65.0 | 8.8 - 11.5 | 10.2 | In |
Put | CRSP260123P00064000 | 0 | 64.0 | 7.4 - 10.8 | 7.4 | In |
Put | CRSP260123P00063000 | 0 | 63.0 | 6.8 - 10.1 | 6.8 | In |
Put | CRSP260123P00062000 | 0 | 62.0 | 6.1 - 9.5 | 6.1 | In |
Put | CRSP260123P00061000 | 0 | 61.0 | 5.5 - 8.9 | 5.5 | In |
Put | CRSP260123P00060000 | 1 | 60.0 | 5.6 - 8.6 | 7.7 | In |
Put | CRSP260123P00059000 | 1 | 59.0 | 5.0 - 7.9 | 7.0 | In |
Put | CRSP260123P00058000 | 1 | 58.0 | 3.7 - 7.3 | 5.73 | In |
Put | CRSP260123P00055000 | 2 | 55.0 | 2.0 - 5.5 | 3.75 | Out |
Put | CRSP260123P00054000 | 2 | 54.0 | 1.5 - 5.1 | 3.6 | Out |
Put | CRSP260123P00053000 | 1 | 53.0 | 1.1 - 4.7 | 3.2 | Out |
Put | CRSP260123P00051000 | 1 | 51.0 | 1.6 - 2.45 | 2.1 | Out |
Put | CRSP260123P00050000 | 4 | 50.0 | 1.2 - 3.9 | 2.39 | Out |
Put | CRSP260123P00045000 | 7 | 45.0 | 0.0 - 2.9 | 1.0 | Out |
Crispr Therapeutics Market Cap Over Time
Market Cap |
| Timeline |
Crispr Total Stockholder Equity
Total Stockholder Equity |
|
Crispr Therapeutics Corporate Management
| Samarth Kulkarni | Chief Business Officer | Profile | |
| James JD | General Secretary | Profile | |
| Susan Kim | Vice Relations | Profile | |
| Craig Mello | Scientific Member | Profile | |
| Lawrence Klein | Chief Officer | Profile | |
| Chad Cowan | Scientific Founder | Profile |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.